The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
The Role of Triglyceride-Rich Lipoprotein Families in the Progression of Atherosclerotic Lesions as Determined by Sequential Coronary Angiography From a Controlled Clinical Trial
Open accessAbstract
We have demonstrated previously in a subset of Monitored Atherosclerosis Regression Study (MARS) subjects with hypercholesterolemia (190 to 295 mg/dL) and documented coronary artery disease that lovastatin significantly reduces cholesterol-rich lipoprotein B (LpB) but has little effect on complex, triglyceride-rich apolipoprotein (apo) B–containing LpB c (the sum of LpB:C, LpB:C:E and LpA-II:B:C:D:E) particles defined by their apolipoprotein composition. This differential effect of lovastatin on apoB-containing lipoprotein families offered the opportunity to determine in the same subset of MARS subjects the independent relationship of LpB and LpB c with the progression of coronary artery disease. Subjects randomized to either lovastatin (40 mg twice daily) or matching placebo were evaluated by coronary angiography before randomization and after 2 years of treatment, and the overall coronary status was judged by a coronary global change score. In the lovastatin-treated group, there were 22 nonprogressors (69%) and 10 progressors (31%), while in the placebo group 13 subjects (42%) were nonprogressors and 18 (58%) were progressors ( P <.03). In the lovastatin-treated group, lipid and lipoprotein parameters did not differ between progressors and nonprogressors except for LpB c and LpA-II:B:C:D:E particle levels, which were statistically higher in progressors ( P =.02). In the placebo-treated group, progressors differed from nonprogressors by having significantly higher levels of triglycerides ( P =.03) and apoC-III in VLDL+LDL ( P =.05), the characteristic constituents of triglyceride-rich lipoproteins. In the placebo- and lovastatin-treated groups combined, progressors had significantly higher on-trial levels of triglycerides ( P =.003), VLDL cholesterol ( P =.005), apoC-III in VLDL+LDL ( P =.008), apoC-III ( P =.01), apoB ( P =.03), and total cholesterol ( P =.04) than nonprogressors. Even after adjustment for treatment group, progressors in the combined placebo- and lovastatin-treated groups had significantly higher levels of LpB c , LpA-II:B:C:D:E, triglycerides, and apoC-III in VLDL+LDL than nonprogressors. Progressors in the placebo-treated, lovastatin-treated, and combined treatment groups had lower levels of LpA-I but not LpA-I:A-II than nonprogressors, and this difference reached statistical significance ( P =.047) in the combined sample adjusted for treatment group. Results of this study show that elevated levels of triglyceride-rich LpB c in general and LpA-II:B:C:D:E in particular contribute significantly to the progression of coronary artery disease. Furthermore, they provide additional evidence for the potentially protective role of LpA-I particles in the atherogenic process and suggest that apolipoprotein-defined lipoprotein families may be more specific prognosticators of coronary artery atherosclerosis progression than lipids and apolipoproteins.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Atherogenesis: a postprandial phenomenon.
Zilversmit, D. B. (1979) · Circulation · doi:10.1161/01.cir.60.3.473 · Cited by 1,701
Hulley, S. B., Rosenman, R. H., Bawol, R. D., & Brand, R. J. (1980) · New England Journal of Medicine · doi:10.1056/nejm198006193022503 · Cited by 702
Blankenhorn, D. H., Azen, S. P., Kramsch, D. M., Mack, W. J., Cashin-Hemphill, L., Hodis, H. N., DeBoer, L. W. V., Mahrer, P. R., Masteller, M. J., Vailas, L. I., et al. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-119-10-199311150-00002 · Cited by 637
Self-citationPlasma Lipoprotein Levels as Predictors of Cardiovascular Death in Women
Bass, K. M. (1993) · Archives of Internal Medicine · doi:10.1001/archinte.1993.00410190045006 · Cited by 331
Blankenhorn, D. H., Alaupovic, P., Wickham, E., Chin, H. P., & Azen, S. P. (1990) · Circulation · doi:10.1161/01.cir.81.2.470 · Cited by 278
Self-citationLipoprotein predictors of the severity of coronary artery disease in men and women.
Reardon, M. F., Nestel, P. J., Craig, I. H., & Harper, R. W. (1985) · Circulation · doi:10.1161/01.cir.71.5.881 · Cited by 266
Shaikh, M., Wootton, R., Nordestgaard, B. G., Baskerville, P., Lumley, J. S., La Ville, A. E., Quiney, J., & Lewis, B. (1991) · Arteriosclerosis and Thrombosis: A Journal of Vascular Biology · doi:10.1161/01.atv.11.3.569 · Cited by 206
Nordestgaard, B. G., Tybjaerg-Hansen, A., & Lewis, B. (1992) · Arteriosclerosis and Thrombosis: A Journal of Vascular Biology · doi:10.1161/01.atv.12.1.6 · Cited by 159
Cited by
Chapman, M. J., Ginsberg, H. N., Amarenco, P., Andreotti, F., Borén, J., Catapano, A. L., Descamps, O. S., Fisher, E., Kovanen, P. T., Kuivenhoven, J. A., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr112 · Cited by 1,227
Atherogenic Lipoprotein Particles in Atherosclerosis
Carmena, R., Duriez, P., & Fruchart, J.-C. (2004) · Circulation · doi:10.1161/01.cir.0000131511.50734.44 · Cited by 494
Sacks, F. M., Alaupovic, P., Moye, L. A., Cole, T. G., Sussex, B., Stampfer, M. J., Pfeffer, M. A., & Braunwald, E. (2000) · Circulation · doi:10.1161/01.cir.102.16.1886 · Cited by 490
Self-citationFruchart, J.-C., Sacks, F., Hermans, M. P., Assmann, G., Brown, W. V., Ceska, R., Chapman, M. J., Dodson, P. M., Fioretto, P., Ginsberg, H. N., et al. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.10.002 · Cited by 463
Evidence that triglycerides are an independent coronary heart disease risk factor
Cullen, P. (2000) · The American Journal of Cardiology · doi:10.1016/s0002-9149(00)01127-9 · Cited by 462
Metadata
- Authors
- Alaupovic, P., Mack, W. J., Knight-Gibson, C., & Hodis, H. N.
- Venue
- Arteriosclerosis, Thrombosis, and Vascular Biology
- Published
- 1997-04
- Volume
- 17
- Issue
- 4
- Pages
- 715-722
- ISSN
- 1079-5642 (ISSN-L)
- 1524-4636
- OpenAlex
- W2036674202
- Cited by
- 184
- References
- 8
- FWCI
- 14.57
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Role of Triglyceride-Rich Lipoprotein Families in the Progression of Atherosclerotic Lesions as Determined by Sequential Coronary Angiography From a Controlled Clinical Trial. https://app.cochat.ai/papers/10.1161/01.atv.17.4.715
- The paper
- Alaupovic, P., Mack, W. J., Knight-Gibson, C., & Hodis, H. N. (1997). The Role of Triglyceride-Rich Lipoprotein Families in the Progression of Atherosclerotic Lesions as Determined by Sequential Coronary Angiography From a Controlled Clinical Trial. Arteriosclerosis, Thrombosis, and Vascular Biology. https://doi.org/10.1161/01.atv.17.4.715
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.